

PIRACETAMUM

SECTION 1: IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING

1.1 PRODUCT IDENTIFIER

Product name: EN: Piracetam
LAT: Piracetamum
NL: Piracetam
FR: Piracétam
DE: Piracetam
N° CAS: 7491-74-9
N° EC: 231-312-7

1.2 RELEVANT IDENTIFIED USES OF THE SUBSTANCE/MIXTURE AND USES ADVISED AGAINST

Identified uses: Active Pharmaceutical Ingredient.

1.3 DETAILS OF THE SUPPLIER OF THE SAFETY DATA SHEET

Company: Magis-Pharma NV
Neerlandweg 24
2610 Wilrijk
Belgium
Telephone: (+32) (0)3 457 11 76
Email: info@magis-pharma.be
Web page: www.magis-pharma.be

1.4 EMERGENCY TELEPHONE NUMBER

Public utility foundation:	Belgisch Antigifcentrum	Centre Antipoisons Belge
Telephone:	(+32) (0)70 245 245	(Service 24/7)
Web page:	www.antigifcentrum.be	www.centreantipoisons.be

SECTION 2: HAZARDS IDENTIFICATION

2.1 CLASSIFICATION OF THE SUBSTANCE/MIXTURE

Classification according to (EC) n° 1272/2008

Not a hazardous substance according to GHS.

This substance is not classified as dangerous according to Directive 67/548/EEC.

2.2 LABEL ELEMENTS

Labelling according to (EC) n° 1272/2008

The product does not need to be labelled according to EC directives or the respective national legislation.

Hazard pictogram(s): Not applicable.
Signal word(s): Not applicable.
Hazard statements: Not applicable.
Precautionary statements: Not applicable.
Additional applicable label elements:



2.3 OTHER HAZARDS

None.

PIRACETAMUM

Publication: 26/08/2024
Revision: XX/XX/XXXX
Version: 00

SECTION 3: COMPOSITION/INFORMATION ON INGREDIENTS

3.1 SUBSTANCES

Product name:	Piracetam
IUPAC name:	2-(2-Oxopyrrolidin-1-yl)acetamide
Synonyms:	1-Acetamido-2-pyrrolidinone 2-Pyrrolidone-N-Acetamide 2-oxo-1-pyrrolidineacetamide Nootropil
N° CAS:	7491-74-9
N° EC:	231-312-7
Molecular Formula:	C ₆ H ₁₀ N ₂ O ₂
Content:	98.0 per cent to 102.0 per cent (dried substance)

3.2 MIXTURES

Not applicable.

SECTION 4: FIRST AID MEASURES

4.1 DESCRIPTION OF FIRST AID MEASURES

After inhalation:	After inhalation, move victim to fresh air. If breathing stops, apply artificial respiration.
After skin contact:	Wash with soap and plenty of water.
After eye contact:	Rinse eyes with water as a precaution.
After ingestion:	Never allow an unconscious person to drink (or eat). Rinse mouth with water.

4.2 MOST IMPORTANT SYMPTOMS AND EFFECTS, BOTH ACUTE AND DELAYED

Not available.

4.3 INDICATION OF ANY IMMEDIATE MEDICAL ATTENTION AND SPECIAL TREATMENT NEEDED

Not available.

SECTION 5: FIREFIGHTING MEASURES

5.1 EXTINGUISHING MEDIA

Suitable extinguishing media:	Use water spray, alcohol-resistant foam, drying powder, or carbon dioxide.
Unsuitable extinguishing media:	Not available.

5.2 SPECIAL HAZARDS ARISING FROM THE SUBSTANCE/MIXTURE

Not available.

5.3 ADVICE FOR FIREFIGHTERS

Surrounding fires:	Not available.
Protection against fire:	If necessary, wear a compressed air mask when fighting fires.
Hazardous combustion products:	Not available.

PIRACETAMUM

Publication: 26/08/2024
Revision: XX/XX/XXXX
Version: 00

SECTION 6: ACCIDENTAL RELEASE MEASURES

6.1 PERSONAL PRECAUTIONS, PROTECTIVE EQUIPMENT AND EMERGENCY PROCEDURES

FOR NON-EMERGENCY PERSONNEL

Avoid dust formation.

FOR EMERGENCY RESPONDERS

Avoid dust formation.

6.2 ENVIRONMENTAL PRECAUTIONS

Do not allow product to enter drains.

6.3 METHODS AND MATERIAL FOR CONTAINMENT AND CLEANING UP

Sweep up and scoop up. Store in suitable and closed containers for disposal.

6.4 REFERENCE TO OTHER SECTIONS

Not available.

SECTION 7: HANDLING AND STORAGE

7.1 PRECAUTIONS FOR SAFE HANDLING

Precautions for safe handling:	Not available.
Personal protection:	Not available.
Technical protective measures:	Provide suitable exhaust ventilation in areas where dust is generated. Normal preventive fire protection measures.
Handling:	Not available.

7.2 CONDITIONS FOR SAFE STORAGE, INCLUDING ANY INCOMPATIBILITIES

Storage:	Not available.
Conditions for safe storage, including any incompatibilities:	Store in a cool place. Keep container tightly closed in a dry and well-ventilated place.
Storage – away from:	Store protected from light.

7.3 SPECIFIC END USE(S)

Active Pharmaceutical Ingredient.

SECTION 8: EXPOSURE CONTROLS/PERSONAL PROTECTION

8.1 CONTROL PARAMETERS

Not available.

8.2 EXPOSURE CONTROLS

The product contains no ingredients for which MAC values have been established.

APPROPRIATE ENGINEERING CONTROL

Hygiene measures: Apply general industrial hygiene.

INDIVIDUAL PROTECTION MEASURES

PIRACETAMUM

Publication: 26/08/2024
Revision: XX/XX/XXXX
Version: 00

Eye/face protection:	Safety glasses.
Skin protection:	Not determined.
Hand protection:	In case of persistent or repeated contact, wear gloves.
Respiratory protection:	Face mask is not required. Wear protection and a dust mask type N95 (US) or type P1 (EN 143), if certain nuisance/value is observed and/or dust particles are wanting. Use respiratory masks tested and approved by official government agencies such as NIOSH (US) or CEN (EU).
Thermal hazards:	Not determined.

ENVIRONMENTAL EXPOSURE CONTROL

Not available.

SECTION 9: PHYSICAL AND CHEMICAL PROPERTIES

9.1 INFORMATION ON BASIC PHYSICAL AND CHEMICAL PROPERTIES

Appearance:	White or almost white powder.
Odour:	Not available.
Odour threshold:	Not available.
pH:	Not available.
Melting/freezing point:	Not available.
Initial boiling point:	Not available.
Boiling range:	Not available.
Flash point:	Not available.
Evaporation rate:	Not available.
Flammability (solid/gas):	Not available.
Upper/lower flammability or explosive limits:	Not available.
Vapour pressure:	Not available.
Vapour density:	Not available.
Relative density:	Not available.
Solubility:	Soluble in ethanol (96 per cent).
Solubility in water:	Freely soluble in water.
Partition coefficient (n-octanol/water):	Not available.
Auto-ignition temperature:	Not available.
Decomposition temperature:	Not available.
Viscosity:	Not available.
Explosive properties:	Not available.
Oxidising properties:	Not available.

9.2 OTHER INFORMATION

Not available.

SECTION 10: STABILITY AND REACTIVITY

MAGIS-PHARMA NV

Neerlandweg 24, 2610 Wilrijk

T: +32 3 457 11 76, F: +32 3 457 43 40, info@magis-pharma.be, www.magis-pharma.be

PIRACETAMUM

Publication: 26/08/2024
Revision: XX/XX/XXXX
Version: 00

10.1 REACTIVITY

Not available.

10.2 CHEMICAL STABILITY

Stable under recommended storage conditions.

10.3 POSSIBILITY OF HAZARDOUS REACTIONS

Not available.

10.4 CONDITIONS TO AVOID

Not available.

10.5 INCOMPATIBLE MATERIALS

Strong oxidising agents.

10.6 HAZARDOUS DECOMPOSITION PRODUCTS

During fire, hazardous decomposition products are formed. - Carbon oxides (CO₂, CO), nitrogen oxides (NO_x).

SECTION 11: TOXICOLOGICAL INFORMATION

11.1 INFORMATION ON TOXICOLOGICAL EFFECTS

Acute toxicity:	LD ₅₀ Oral - mouse - 2,000 mg/kg
Skin corrosion/irritation:	Not available.
Serious eye damage/irritation:	Not available.
Respiratory/skin sensitisation:	Not available.
Germ cell mutagenicity:	Not available.
Carcinogenicity:	IARC: No component of this product, to the extent present at a concentration greater than or equal to 0.1% has been identified as a probable, possible or confirmed carcinogen by IARC.
Reproductive toxicity:	Not available.
Summary of evaluation of the CMR properties:	Not available.
STOT-single exposure:	Not available.
STOT-repeated exposure:	Not available.
Aspiration Hazard:	Not available.
Other:	RTECS: UX9660500

11.2 ADDITIONAL INFORMATION ON POTENTIAL ADVERSE HUMAN HEALTH EFFECTS AND SYMPTOMS

Eye contact:	May cause eye irritation.
Skin contact:	May be harmful if absorbed through the skin. May cause skin irritation.
Inhalation:	May be harmful if inhaled. May cause irritation of the respiratory system.
Ingestion:	May be harmful if swallowed.
Aspiration:	Not available.

SECTION 12: ECOLOGICAL INFORMATION

12.1 TOXICITY

Not available.

PIRACETAMUM

Publication: 26/08/2024
Revision: XX/XX/XXXX
Version: 00

12.2 PERSISTENCE AND DEGRADABILITY

Not available.

12.3 BIOACCUMULATIVE POTENTIAL

Not available.

12.4 MOBILITY IN SOIL

Not available.

12.5 RESULTS OF PBT AND VPVB ASSESSMENT

Not available.

12.6 OTHER ADVERSE EFFECTS

Not available.

SECTION 13: DISPOSAL CONSIDERATIONS

13.1 WASTE TREATMENT METHODS

Product

Comply with all national, provincial and municipal environmental regulations.

Contaminated packaging

Dispose of as unused product.

SECTION 14: TRANSPORT INFORMATION

Transport information according to ADR/RID/IMDG/ICAO/IATA

14.1 UN NUMBER

ADR/ RID(Land),IMDG(Sea), Not classified.

IATA/ICAO (Air) :

14.2 UN PROPER SHIPPING NAME

ADR/ RID(Land),IMDG(Sea), Not dangerous goods

IATA/ICAO (Air) :

14.3 TRANSPORT HAZARD CLASS(ES)

ADR/ RID(Land),IMDG(Sea), Not classified.

IATA/ICAO (Air) :

14.4 PACKING GROUP

ADR/ RID(Land),IMDG(Sea), Not classified.

IATA/ICAO (Air) :

14.5 ENVIRONMENTAL HAZARDS

ADR/ RID(Land),IMDG(Sea), Not classified.

IATA/ICAO (Air) :

14.6 SPECIAL PRECAUTIONS FOR USER

Not available.

14.7 TRANSPORT IN BULK ACCORDING TO ANNEX II OF MARPOL AND THE IBC CODE

Not available.

14.8 ADDITIONAL TRANSPORT INFORMATION

PIRACETAMUM

Publication: 26/08/2024
Revision: XX/XX/XXXX
Version: 00

Not available.

SECTION 15: REGULATORY INFORMATION

15.1 SAFETY, HEALTH AND ENVIRONMENTAL REGULATIONS/LEGISLATION SPECIFIC FOR THE SUBSTANCE/MIXTURE

Hazard symbol: Not applicable.
Risk phrases: Not applicable.
Safety phrases: Not applicable.

15.2 CHEMICAL SAFETY ASSESSMENT

Not available.

SECTION 16: OTHER INFORMATION

16.1 CHANGES SINCE THE PREVIOUS VERSION

Not applicable.

16.2 ABBREVIATIONS AND ACRONYMS USED

ADR: European Agreement concerning the International Carriage of Dangerous Goods by Road
CAS: Chemical Abstracts Service (division of the American Chemical Society)
EC (number): European Community (number)
IATA: International Air Transport Association
ICAO: International Civil Aviation Organization
IMDG: International Maritime Code for Dangerous Goods
IUPAC: International Union of Pure and Applied Chemistry
PBT: Persistent, Bioaccumulative and Toxic substance
RID: Regulations Concerning the International Transport of Dangerous Goods by Rail
STOT: Specific Target Organ Toxicity
UN (number): United Nations (number)
vPvB: very Persistent and very Bioaccumulative

16.3 KEY LITERATURE REFERENCES/SOURCES FOR DATA

European Chemicals Agency.
<https://www.echa.europa.eu/web/guest/information-on-chemicals/cl-inventory-database/>

16.4 METHOD OF CLASSIFICATION IN CASE OF MIXTURE

Not applicable.

16.5 RELEVANT HAZARD STATEMENTS AND/OR PRECAUTIONARY STATEMENTS

For information on hazard and/or precautionary statements refer to section 2 up to and including section 15.

16.6 TRAINING ADVISEMENT

Not available

16.7 NOTICE FOR USER(S)

The information provided in this MSDS has been established in accordance with Commission Regulation (EU) 2015/830 of 28 May 2015, amending Regulation (EC) No 1907/2006 of the European Parliament and of the Council, on the Registration, Evaluation, Authorization and Restriction of Chemicals (REACH), establishing the European Chemicals

PIRACETAMUM

Publication: 26/08/2024
Revision: XX/XX/XXXX
Version: 00

Agency, amending Directive 1999/45/EC and repealing Council Regulation (EEC) No 793/93 and Commission Regulation (EC) No 1488/94, as well as Council Directive 76/769/EEC and Directives 91/155/EEC, 93/67/EEC, 93/105/EC and 2000/21/EC of the Commission.

This MSDS is intended to provide a brief summary of our knowledge and guidance regarding the use of this material. The information has been compiled from sources considered to be dependable and is accurate to the best of the Magis-Pharma NV's knowledge. However, the information is provided without any representation or warranty, expressed or implied regarding its accuracy or correctness. Magis-Pharma NV cannot assume responsibility for adverse events which may occur in the use and/or misuse of this product and expressly disclaims liability for loss, damage and/or expense arising out of or in any way connected with the handling, storage, use and/or disposal of this product.

16.8 DEPARTMENT ISSUING MSDS

Magis-Pharma NV
info@magis-pharma.be

